We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease (ETHERAL-US)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03867253
Recruitment Status : Completed
First Posted : March 7, 2019
Last Update Posted : March 5, 2021
Alzheimer's Drug Discovery Foundation
Information provided by (Responsible Party):
Oryzon Genomics S.A.

Brief Summary:
This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.

Condition or disease Intervention/treatment Phase
Mild to Moderate Alzheimer's Disease Drug: ORY-2001 Low dose Drug: ORY-2001 High dose Drug: Placebo Phase 2

Detailed Description:

This phase IIa study is a double-blind, randomized, parallel-group and multicenter study with a placebo-controlled 24-week treatment period followed by a no placebo-controlled 24-week extension period.

It is planned to randomise 25 patients. In the double-blind placebo-controlled treatment period, all patients will be randomized between two doses of ORY-2001 and placebo. In the double-blind no placebo-controlled extension period, patients in the placebo arm will be re-allocated in one of the two different dose levels of ORY-2001. Randomization will be stratified by cognitive impairment severity.

An independent Data Monitoring Committee (DMC) will review un-blinded safety data throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease
Actual Study Start Date : May 16, 2019
Actual Primary Completion Date : November 12, 2020
Actual Study Completion Date : November 12, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: ORY-2001 Low dose
0.6mg ORY-2001 capsule
Drug: ORY-2001 Low dose
0.6mg ORY-2001 capsule

Active Comparator: ORY-2001 High dose
1.2mg ORY-2001 capsule
Drug: ORY-2001 High dose
1.2mg ORY-2001 capsule

Placebo Comparator: Placebo
Placebo capsule
Drug: Placebo
Placebo capsule

Primary Outcome Measures :
  1. Treatment Emergent Adverse Events [ Time Frame: Week 24 ]
    Number, frequency and severity of Treatment Emergent Adverse Events (TEAEs) including serious TEAEs.

  2. Treatment Emergent Adverse Events [ Time Frame: Week 48 ]
    Number, frequency and severity of Treatment Emergent Adverse Events (TEAEs) including serious TEAEs.

  3. Withdrawn patients due to TEAEs [ Time Frame: Week 24 ]
    Number and percentage of withdrawn patients due to TEAEs

  4. Withdrawn patients due to TEAEs [ Time Frame: Week 48 ]
    Number and percentage of withdrawn patients due to TEAEs

Secondary Outcome Measures :
  1. Cohen-Mansfield Agitation Inventory (CMAI) [ Time Frame: 48 weeks ]
    Change from baseline to week 48 compared to placebo

  2. Clinician version of the Apathy Evaluation Scale (AES-C) [ Time Frame: 48 weeks ]
    Change from baseline to week 48 compared to placebo

  3. 14-item Alzheimer's Disease Assessment Scale-Cognitive [ Time Frame: 48 weeks ]
    Change from baseline to week 48 compared to placebo

  4. Computerized Cognitive Test battery [ Time Frame: 48 weeks ]
    Change from baseline to week 48 compared to placebo

  5. Mini-Mental State Examination (MMSE) [ Time Frame: 48 weeks ]
    Change from baseline compared to placebo

  6. Clinical Dementia Rating Scale Sum of Boxes [ Time Frame: 48 weeks ]
    Change from baseline to week 48 compared to placebo

  7. Cornell Scale for Depression in Dementia (CSDD) [ Time Frame: 48 weeks ]
    Change from baseline to week 48 compared to placebo

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Probable Alzheimer's Disease (AD) diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
  • MMSE score at Screening and Baseline Visits of at least 16 and not greater than 26
  • Evidence of the AD pathophysiological process indicated by decreased levels of amyloid antigen binding (AB) and increased levels of total Tau protein or phospho-Tau protein in cerebrospinal fluid (CSF)
  • Outpatient consulting a general practitioner, or a psychiatrist/neurologist/geriatrician
  • Knowledgeable and reliable close relative/caregiver who will accompany the patient to all clinic visits during the study
  • Daily treatment with the same acetylcholinesterase inhibitor on a stable dose
  • Fertile male and female must use highly effective contraception, from the Screening Visit until 90 days after last dose.
  • Signed informed consent by patient (or legal representative, if applicable) and a close relative/caregiver prior to the initiation of any study specific procedure

Exclusion Criteria:

  • Failure to perform screening or baseline examinations
  • Hospitalization or change of concomitant medication 1 month prior to Screening visit or during Screening Period
  • Clinical, laboratory or neuroimaging findings consistent with:

    1. Other primary degenerative dementia;
    2. Other neurodegenerative condition;
    3. Cerebrovascular disease;
    4. Other central nervous system diseases;
  • A current Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of major depression, schizophrenia or bipolar disorder
  • Positive results for tuberculosis, human immunodeficiency virus (HIV), hepatitis C or hepatitis B (hepatitis B surface antigen [HbsAg]) serology at the Screening Visit
  • Clinically significant, advanced or unstable disease that may interfere with evaluation.
  • Disability that may prevent the patients from completing all study requirements.
  • Chronic drug intake of forbidden concomitant medication.
  • Treatment with anti-amyloid beta or anti-Tau protein monoclonal antibodies or other disease modifying strategies within three months or five half-lives, whichever is longer, prior to the Screening Visit
  • Treatment with an active vaccine targeting amyloid beta or Tau protein
  • Suspected or known drug or alcohol abuse
  • Metallic implants or any other cause precluding the performance of brain MRI
  • Enrolment in another investigational study or intake of investigational drug within the previous 3 months since the last dose
  • Suicide attempt within the last year or significant risk of suicide (in the opinion of the investigator, defined as a "yes" to suicidal ideation questions 4 or 5, or answering "yes" to suicidal behavior on the Columbia-Suicide Severity Rating Scale within the past 12 months)
  • Any condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03867253

Layout table for location information
United States, Florida
Alzheimer's Research and Treatment Center
Wellington, Florida, United States, 33414
United States, Georgia
Columbus Memory Center
Columbus, Georgia, United States, 31909
United States, New Jersey
Princeton Medical Institute
Princeton, New Jersey, United States, 08540
United States, Pennsylvania
Abington Neurological Associates Ltd.
Willow Grove, Pennsylvania, United States, 191090
Sponsors and Collaborators
Oryzon Genomics S.A.
Alzheimer's Drug Discovery Foundation
Layout table for investigator information
Study Director: Michael Ropacki, MD Oryzon Genomics S.A.
Layout table for additonal information
Responsible Party: Oryzon Genomics S.A.
ClinicalTrials.gov Identifier: NCT03867253    
Other Study ID Numbers: CL05-ORY-2001US
First Posted: March 7, 2019    Key Record Dates
Last Update Posted: March 5, 2021
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Oryzon Genomics S.A.:
Alzheimer's Disease, ORY-2001
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders